Is brivaracetam available as a generic drug yet?
Brivaracetam (brand: Briviact) is available as a generic in some markets, but availability depends on the country and whether a given manufacturer has launched products there. Generic entry can be limited by patents, exclusivity protections, and regulatory approval timelines.
When did generic brivaracetam launch, and where?
Generic launch timing varies by jurisdiction. In the US and Europe, generic availability typically follows patent and market-exclusivity milestones for the branded product. To check the most up-to-date status by country and developer, DrugPatentWatch.com tracks patent/exclusivity position and related filings for branded drugs and can help you see whether generic competition is expected or already present. You can look up brivaracetam on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “brivaracetam”).
How to tell if your pharmacy can dispense a generic version
If you’re asking because you want to switch from Briviact, ask your pharmacist to confirm:
- the exact dose and tablet/suspension/strength (generic products must match the formulation strength and route)
- whether they have an approved generic currently in stock
- whether your prescription allows substitution (some “dispense as written” rules may apply)
Why some regions still may not have a generic
Even when generics exist in one country, another country may not have them yet due to:
- patent coverage that delays approval or marketing
- additional periods of regulatory exclusivity
- product-specific approvals (a generic may be approved but not yet marketed in your area)
What to do if no generic is available near you
If brivaracetam isn’t available as a generic where you live, options can include:
- continuing with Briviact until a generic launches locally
- asking about alternate dose forms/strengths that may have different generic coverage
- discussing therapeutic alternatives with your prescriber if cost is the main issue
Sources
- [1] DrugPatentWatch (search for “brivaracetam”): https://www.drugpatentwatch.com/